0001213900-23-065046 | 10-Q | XBRL Viewer

Six months ended June 30,

(in thousands)

Outstanding stock options

Restricted stock and unit awards

Stock purchase warrants

Print Document View Excel Document

The Company (Details)	Jun. 30, 2023 subsidiary
The Company
Number of wholly owned subsidiaries	2

Accrued Expenses and Other Current Liabilities

6 Months Ended

Jun. 30, 2023

Accrued Expenses and Other Current Liabilities

Accrued Expenses and Other Current Liabilities

Note 7. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities as of June 30, 2023 and December 31, 2022 consisted of the following:

(in thousands)	June 30, 2023		December 31, 2022
Accrued professional fees	$	483	$	524
Accrued bonuses and incentive compensation		1,436		2,042
Accrued litigation legal fees expense		1,035		1,001
Accrued insurance expense		24		264
Accrued vacation and other employee related expenses		739		534
Accrued severance and other related charges		207		—
Accrued valued-added tax		180		133
Deferred revenue		36		152
Other		70		192
	$	4,210	$	4,842

Finance and Security Agreement

On July 5, 2022, the Company entered into a Commercial Insurance Premium Finance and Security Agreement (the "2022 Agreement"). The 2022 Agreement provides for a single borrowing by the Company of approximately $783,000 with a nine-month term and an annual interest rate of 2.49%. The proceeds from this transaction were used to partially fund the premiums due under certain of the Company's insurance policies. All borrowings were repaid as of June 30, 2023. During the three and six months ended June 30, 2023, the Company recognized $2,250 and $3,867 in interest expense, respectively. On July 5, 2023, the Company entered into a new Commercial Insurance Premium Finance and Security Agreement. See Note 14. Subsequent Events.

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash flows from operating activities:
Net loss	$ (10,770)	$ (10,919)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	755	1,529
Depreciation and amortization	444	247
Net noncash lease expense	30	21
Inventory reserve charge	65
Increase in provision for bad debts	28
Changes in operating assets and liabilities:
Accounts receivable, net	135	(137)
Inventories	(71)	289
Prepaid expenses and other current assets	723	823
Accounts payable	155	1,115
Accrued expenses and other current liabilities	(631)	(963)
Operating lease liabilities	(35)	(29)
Net cash used in operating activities	(9,172)	(8,024)
Cash flows from investing activities:
Purchase of equipment	(91)
Net cash used in investing activities	(91)
Cash flows from financing activities:
Net cash provided by financing activities
Effect of changes in exchange rates on cash and cash equivalents	(7)	(85)
Net decrease in cash and cash equivalents and restricted cash	(9,270)	(8,109)
Cash and cash equivalents and restricted cash – beginning of period	17,962	34,689
Cash and cash equivalents and restricted cash – end of period	8,692	26,580
Supplemental cash flows disclosures:
Proceeds from sale of state net operating losses	211	445
Interest paid	$ 4	$ 4

Severance and other related charges - Additional Information (Details)	6 Months Ended
	Jun. 30, 2023 USD ($)
Selling, General and Administrative
Defined Benefit Plan Disclosure [Line Items]
Postemployment benefits outstanding payable	$ 207,000
Two Former Employees
Defined Benefit Plan Disclosure [Line Items]
Postemployment benefits liability	$ 332,000

Leases - Future Minimum Lease Payments under Non-Cancellable Operating Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Leases
Remainder of 2023	$ 82
2024	168
2025	171
2026	161
2027	157
2028 and thereafter	216
Total future minimum lease payments	955
Less: Amounts representing interest	(291)
Total	$ 664	$ 699

Summary of Significant Accounting Policies - Additional Information (Details)			6 Months Ended
	Feb. 15, 2023	Feb. 13, 2023 d $ / shares	Jun. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Accounting Policies [Line Items]
Finite-Lived License Agreements, Gross			$ 0
Reverse stock split ratio	1-for-15
Reverse stock split, Stock Price Trigger \| $ / shares		$ 1
Reverse stock split, Threshold Consecutive Trading Days \| d		10
Licensing Agreements [Member]
Accounting Policies [Line Items]
Net book value of licensed devices			$ 724,000	$ 538,000
Minimum [Member]
Accounting Policies [Line Items]
Estimated useful life			12 months
Reverse stock split ratio		1-for-5
Maximum [Member]
Accounting Policies [Line Items]
Estimated useful life			36 months
Reverse stock split ratio		1-for-50

Revenue - Summary of Net Sales Disaggregated by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation Of Revenue [Line Items]
Total Net Sales	$ 3,551	$ 2,157	$ 6,331	$ 4,056
United States
Disaggregation Of Revenue [Line Items]
Total Net Sales	3,127	1,690	5,497	3,284
United Kingdom
Disaggregation Of Revenue [Line Items]
Total Net Sales	384	355	705	621
Other
Disaggregation Of Revenue [Line Items]
Total Net Sales	22	64	65	103
JAPAN
Disaggregation Of Revenue [Line Items]
Total Net Sales	$ 18	$ 48	$ 64	$ 48

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Net Loss Per Share

6 Months Ended

Jun. 30, 2023

Net Loss Per Share

Net Loss Per Share

Note 9. Net Loss Per Share

Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding adjusted to give effect to potentially dilutive securities. Restricted stock and unit awards, stock options, and warrants have not been included in the diluted loss per share calculation as their inclusion would have had an anti-dilutive effect.

The potential common stock equivalents that have been excluded from the computation of diluted loss per share consist of the following:

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

Basis of Presentation

(a)	Basis of Presentation

The accompanying condensed consolidated financial statements were prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) and with instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934, as amended. In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments necessary for a fair presentation of the Company’s condensed consolidated financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes for the year ended December 31, 2022 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 8, 2023. The results for the three and six months ended June 30, 2023 are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.

At a special stockholders meeting held on February 13, 2023, the Company's stockholders approved an amendment to the Company's certificate of incorporation to effect of a reverse stock split of the Company's common stock at a ratio between 1-for-5 to 1-for-50 in order to achieve a minimum bid price of $1.00 per share for a minimum of 10 consecutive trading days, as required for continued listing of the common stock on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The board of directors authorized a 1-for-15 ratio for the reverse stock split, which became effective on February 15, 2023. The accompanying condensed consolidated financial statements and notes to condensed consolidated financial statements give retroactive effect to the reverse stock split for all prior periods presented.

Principles of Consolidation

(b)	Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of electroCore and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

(c)	Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include allowances for doubtful accounts, trade credits, rebates, co-payment assistance and sales returns, valuation of inventory, estimated useful life of licensed products and cloud computing arrangements, stock compensation, incremental borrowing rate and contingencies.

Cash, Cash Equivalents and Restricted Cash

(d)	Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash to the balance reflected on the Condensed Consolidated Statement of Cash Flows for June 30, 2023 and 2022:

(in thousands)	June 30, 2023		June 30, 2022
Cash and cash equivalents	$	8,442	$	26,330
Restricted cash		250		250
Total cash, cash equivalents and restricted cash	$	8,692	$	26,580

As of June 30, 2023 and December 31, 2022, cash equivalents represented funds held in a money market account.

Restricted Cash

(e)	Restricted Cash

The Company's restricted cash consists of cash that the Company is contractually obligated to maintain in accordance with the terms of its corporate credit card arrangement with Citibank, N.A and established in April 2022.

Licensed Products

(f)	Licensed Products

The Company licenses a portion of its devices through its cash pay channels. The cost of these licensed devices is capitalized and included in Other Assets in the accompanying Condensed Consolidated Balance Sheets at June 30, 2023 and December 31, 2022, and is being recognized as cost of goods sold on the straight-line method over the estimated 12-36 month useful life of the devices. If certain licensed devices are returned and no longer meet quality specifications or the carrying amount of certain licensed devices are no longer deemed to be recoverable, the Company records a charge to cost of goods sold to write down such licensed devices to zero. The net book value of these licensed devices at June 30, 2023 and December 31, 2022 was $724,000 and $538,000, respectively. Changes in the value of these licensed devices in Other Assets is captured on the Statement of Cash Flows with inventories.

Prior Year Presentation

(g)	Prior Year Presentation

Prior year presentation has been conformed to current year presentation.

Revenue

6 Months Ended

Jun. 30, 2023

Revenue

Revenue

Note 4. Revenue

Product Net Sales

(in thousands)	Three months ended June 30,				Six months ended June 30,
Channel		2023		2022		2023		2022
Rx gammaCore - Department of Veteran Affairs and Department of Defense	$	2,081	$	1,190	$	3,786	$	2,430
Rx gammaCore - U.S. Commercial		441		465		871		741
Outside the United States		424		467		834		772
Truvaga		290		—		437		—
TAC-STIM		311		—		399		—
Other		4		35		4		113
	$	3,551	$	2,157	$	6,331	$	4,056

Geographical Net Sales

The following table presents net sales disaggregated by geographic market:

	Three months ended June 30,				Six months ended June 30,
(in thousands)		2023		2022		2023		2022
Product revenue
United States	$	3,127	$	1,690	$	5,497	$	3,284
United Kingdom		384		355		705		621
Other		22		64		65		103
License revenue
Japan		18		48		64		48
Total Net Sales	$	3,551	$	2,157	$	6,331	$	4,056

The Company generally invoices the customer and recognizes revenue once its performance obligations are satisfied, at which point payment is unconditional. Agreed upon payment terms with customers are within 30 days of shipment. Accordingly, contracts with customers do not include a significant financing component.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

+ Details

Stock Based Compensation - Additional Information (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2023 USD ($)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation cost related to unvested awards	$ 1,300
Unrecognized compensation expected to be recognized	1 year 2 months 12 days
Intrinsic value	$ 0
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate	50.00%
Non Employee Director [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	12 months
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	3 years
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years
Stock Units \| Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	2 years
Stock Units \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Vesting period	4 years

Stockholders' Equity - Additional Information (Details) - $ / shares	Feb. 15, 2023	Feb. 13, 2023	Jun. 30, 2023	Mar. 06, 2023
Stock Purchase Agreement [Line Items]
Stockholders' Equity, Reverse Stock Split	1-for-15
Minimum
Stock Purchase Agreement [Line Items]
Stockholders' Equity, Reverse Stock Split		1-for-5
Maximum
Stock Purchase Agreement [Line Items]
Stockholders' Equity, Reverse Stock Split		1-for-50
Series A Preferred Stock [Member]
Stock Purchase Agreement [Line Items]
Preferred stock redemption, Share				80,000
Preferred Stock
Stock Purchase Agreement [Line Items]
Preferred Stock, Redemption Price Per Share			$ 0.01
Number of basis shares to receive redemption amount			10

Going Concern, Significant Risks and Uncertainties

6 Months Ended

Jun. 30, 2023

Going Concern, Significant Risks and Uncertainties

Going Concern, Significant Risks and Uncertainties

Note 3. Going Concern, Significant Risks and Uncertainties

Going Concern

The Company has experienced significant net losses and cash used in operations, and it expects to continue to incur net losses and cash used in operations for the near future as it works to increase market acceptance of its medical devices and wellness products. The Company has never been profitable and has incurred net losses and cash used in operations in each year since its inception.

Sales to the United States Department of Veteran Affairs comprised 59.8% of the Company's revenue during the six months ended June 30, 2023. The Company expects that a majority of its remaining 2023 sales will be made pursuant to its qualifying contract under the Federal Supply Schedule, or FSS, which was secured by the Company in December 2018, as well as open market sales to individual facilities within the government channels. The FSS is scheduled to expire on January 15, 2024. The Company has submitted a renewal application for extension of its qualifying contract under the FSS from the Department of Veterans Affairs Office of Procurement and Logistics, but there is no assurance the FSS will be renewed, if at all, or renewed at terms favorable to the Company.

The Company has historically funded its operations from the sale of its common stock. On July 31, 2023, the Company entered into a registered direct offering with a certain institutional and accredited investors, and concurrent private placements with certain of the Company’s officers and directors, resulting in net proceeds to the Company of approximately $7.5 million after deducting the placement agent fees and expenses, and other offering expenses payable by the Company. See Note 14. Subsequent Events, Securities Purchase Agreements.

The Company’s expected cash requirements for the next 12 months and beyond are largely based on the commercial success of its products. The Company believes its cash and cash equivalents and anticipated revenues will enable it to fund its operating expenses, working capital, and capital expenditure requirements, as currently planned, through 12 months from the date of the accompanying financial statements. There are significant risks and uncertainties as to its ability to achieve these operating results. Due to the risks and uncertainties, there can be no assurance that the Company will have sufficient cash flow and liquidity to fund its planned activities, which could force it to significantly reduce or curtail its activities and, ultimately, potentially cease operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date these accompanying financial statements are issued. The accompanying financial statements do not include any adjustment that might result from the outcome of this uncertainty.

Concentration of Revenue Risks

The Company earns a significant amount of its revenue (i) in the United States from the Department of Veterans Affairs and Department of Defense ("VA/DoD") pursuant to its qualifying contract under the FSS and open market sales to individual Department of Veterans Affairs facilities, and (ii) in the United Kingdom from the National Health Service. The VA/DoD and National Health Service comprise those customers of the Company that each account for 10% or more of total net sales during the six months ended June 30, 2023 and 2022. The following table reflects the respective concentration as a percentage of the Company's net sales for the three and six months ended June 30, 2023 and 2022:

	Three months ended June 30,				Six months ended June 30,
	2023		2022		2023		2022
Revenue channel:
Rx gammaCore - VA/DoD	58.6	%	55.1	%	59.8	%	60.4	%
National Health Service	9.8	%	16.4	%	9.9	%	15.3	%

No VA/DOD facility accounted for more than 10% of total VA/DoD net sales during the six months ended June 30, 2023. During the three and six months ended June 30, 2023 and 2022, one facility accounted for more than 10% of net sales from the National Health Service.

Foreign Currency Exchange

The Company has foreign currency exchange risk related to revenue and operating expenses in currencies other than the local currencies in which it operates. The Company is exposed to currency risk from the potential changes in functional currency values of its assets, liabilities, and cash flows denominated in foreign currencies.

Stock Based Compensation - Schedule of Recognized Stock Compensation for Equity Awards (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation	$ 183	$ 752	$ 755	$ 1,529
Selling, General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation	115	676	625	1,381
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation	61	68	118	134
Cost of Goods Sold
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation	$ 7	$ 8	$ 12	$ 14

Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2023

Net Loss Per Share

Schedule of common stock equivalents excluded from computation of diluted loss per share

The Company

6 Months Ended

Jun. 30, 2023

The Company

The Company

Note 1. The Company

electroCore, Inc. and its subsidiaries (“electroCore” or the “Company”) is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. The Company’s focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.

electroCore, headquartered in Rockaway, NJ, has two wholly owned subsidiaries: electroCore UK Ltd and electroCore Germany GmbH. The Company has paused operations in Germany, with sales into the country and the rest of Europe being managed by electroCore UK Ltd.

Condensed Consolidated Statements of Equity - USD ($) shares in Thousands, $ in Thousands	Total	Preferred Stock	Common Stock	Additional paid-in capital	Accumulated deficit	Accumulated other comprehensive income (loss)
Balances at Dec. 31, 2021	$ 36,582		$ 5	$ 160,772	$ (124,208)	$ 13
Balances, Mezzanine Equity at Dec. 31, 2021
Balances, shares at Dec. 31, 2021			4,714
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(5,582)				(5,582)
Other comprehensive income	(27)					(27)
Issuance of stock related to employee compensation plans, net of forfeitures
Issuance of stock related to employee compensation plans, net of forfeitures, shares			1
Share based compensation	777			777
Balances at Mar. 31, 2022	31,750		$ 5	161,549	(129,790)	(14)
Balances, Mezzanine Equity at Mar. 31, 2022
Balances, shares at Mar. 31, 2022			4,715
Balances at Dec. 31, 2021	36,582		$ 5	160,772	(124,208)	13
Balances, Mezzanine Equity at Dec. 31, 2021
Balances, shares at Dec. 31, 2021			4,714
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(10,919)
Other comprehensive income	(85)
Balances at Jun. 30, 2022	27,107		$ 5	162,301	(135,127)	(72)
Balances, Mezzanine Equity at Jun. 30, 2022
Balances, shares at Jun. 30, 2022			4,742
Balances at Mar. 31, 2022	31,750		$ 5	161,549	(129,790)	(14)
Balances, Mezzanine Equity at Mar. 31, 2022
Balances, shares at Mar. 31, 2022			4,715
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(5,337)				(5,337)
Other comprehensive income	(58)					(58)
Issuance of stock related to employee compensation plans, net of forfeitures
Issuance of stock related to employee compensation plans, net of forfeitures, shares			27
Share based compensation	752			752
Balances at Jun. 30, 2022	27,107		$ 5	162,301	(135,127)	(72)
Balances, Mezzanine Equity at Jun. 30, 2022
Balances, shares at Jun. 30, 2022			4,742
Balances at Dec. 31, 2022	17,086		$ 5	163,520	(146,370)	(69)
Balances, Mezzanine Equity at Dec. 31, 2022
Balances, shares at Dec. 31, 2022		71	4,745
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(5,867)				(5,867)
Other comprehensive income	56					56
Issuance of stock related to employee compensation plans, net of forfeitures
Issuance of stock related to employee compensation plans, net of forfeitures, shares			1
Preferred stock redemption
Preferred stock redemption, shares		(71)
Share based compensation	572			572
Balances at Mar. 31, 2023	11,847		$ 5	164,092	(152,237)	(13)
Balances, Mezzanine Equity at Mar. 31, 2023
Balances, shares at Mar. 31, 2023			4,746
Balances at Dec. 31, 2022	17,086		$ 5	163,520	(146,370)	(69)
Balances, Mezzanine Equity at Dec. 31, 2022
Balances, shares at Dec. 31, 2022		71	4,745
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(10,770)
Other comprehensive income	(7)
Balances at Jun. 30, 2023	7,064		$ 5	164,275	(157,140)	(76)
Balances, Mezzanine Equity at Jun. 30, 2023
Balances, shares at Jun. 30, 2023			4,752
Balances at Mar. 31, 2023	11,847		$ 5	164,092	(152,237)	(13)
Balances, Mezzanine Equity at Mar. 31, 2023
Balances, shares at Mar. 31, 2023			4,746
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(4,903)				(4,903)
Other comprehensive income	(63)					(63)
Issuance of stock related to employee compensation plans, net of forfeitures
Issuance of stock related to employee compensation plans, net of forfeitures, shares			6
Share based compensation	183			183
Balances at Jun. 30, 2023	7,064		$ 5	$ 164,275	$ (157,140)	$ (76)
Balances, Mezzanine Equity at Jun. 30, 2023
Balances, shares at Jun. 30, 2023			4,752

Stock Based Compensation - Summary of Activity Related to Restricted Stock and Deferred Stock Units Granted (Details) - Stock Units shares in Thousands	6 Months Ended
	Jun. 30, 2023 $ / shares shares
Number of Shares
Number of Shares, Nonvested, Ending	127
Number of Shares, Granted
Number of Shares, Vested	(11)
Number of Shares, Cancelled
Number of Shares, Nonvested, Begining	116
Weighted Average Grant Date Fair Value
Weighted Average Exercise Price, Beginning balance \| $ / shares	$ 11.85
Weighted Average Exercise Price, Ending balance \| $ / shares	$ 11.06

Stock Based Compensation

6 Months Ended

Jun. 30, 2023

Stock Based Compensation

Stock Based Compensation

Note 11. Stock Based Compensation

The following table presents a summary of activity related to stock options during the six months ended June 30, 2023:

	Number of Options (in thousands)			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)
Outstanding, January 1, 2023	$	440		$	55.65		7.5
Granted		3
Exercised		—
Cancelled		(108	)
Outstanding, June 30, 2023	$	335		$	58.79		7.0
Exercisable, June 30, 2023	$	236		$	76.92		6.6

The intrinsic value is calculated as the difference between the fair market value at June 30, 2023 and the exercise price per share of the stock options. As of June 30, 2023, all options outstanding had no material intrinsic value. The options granted to employees generally vest over a three or four-year period.

The following table presents a summary of activity related to restricted and deferred stock units (“Stock Units”) granted during the six months ended June 30, 2023:

	Number of Shares (in thousands)			Weighted Average Grant Date Fair Value
Nonvested, January 1, 2023		127		$	11.85
Granted		—
Vested		(11	)
Cancelled		—
Nonvested, June 30, 2023		116		$	11.06

In general, Stock Units granted to employees vest over two to four-year periods.

Immediately following the Company’s annual meeting of stockholders, the Company generally grants each non-employee director an equity award that vests over a 12-month period. Upon a non-employee director’s initial appointment or election to the board of directors, the Company grants such non-employee director an equity award subject to vesting as determined by the board of directors.

The Company recognized stock compensation expense for its equity awards as follows:

	Three months ended June 30,					Six months ended June 30,
(in thousands)	2023		2022		2023		2022
Selling, general and administrative	$	115	$	676	$	625	$	1,381
Research and development		61		68		118		134
Cost of goods sold		7		8		12		14
Total expense	$	183	$	752	$	755	$	1,529

Total unrecognized compensation cost related to unvested awards as of June 30, 2023 was $1.3 million and is expected to be recognized over the next 1.2 years

Valuation Information for Stock-Based Compensation

The fair value of each stock option award during the three and six months ended June 30, 2023 and 2022 was estimated on the date of grant using the Black-Scholes model. Expected volatility was based on historical common stock volatility of the Company’s peers. Beginning in December 2022, the Company began incorporating its historical common stock volatility at a weighting of 50% of the total composite volatility rate. During the remainder of 2023, the Company will continue to evaluate the volatility rate used to value stock options. The risk-free interest rate was based on the average U.S. Treasury rate that most closely resembled the expected life of the related award. The expected term of the award was calculated using the simplified method. No dividend was assumed as the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.

The weighted average assumptions used in the Black-Scholes option pricing model in valuing stock options granted in the three and six months ended June 30, 2023 and 2022 are summarized in the table below.

	Six months ended June 30,
	2023				2022
Fair value at grant date	$	3.46		$	7.95
Expected volatility	114.0		%		84.0	%
Risk-free interest rate	3.9		%		1.7	%
Expected holding period, in years	6.0				6.0
Dividend yield		—	%		—	%

Contingencies - Additional Information (Details)	Jul. 17, 2020 INVESTORS
Class Of Warrant Or Right [Line Items]
Number of investors as defendants	2

Inventories - Additional Information (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Inventory [Line Items]
Reserves for obsolete inventory	$ 0.3	$ 0.7
Noncurrent inventory raw materials	0.6	0.1
Noncurrent inventory work in process	$ 0.8	$ 2.1

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

Schedule of cash equivalents and restricted cash

(in thousands)	June 30, 2023		June 30, 2022
Cash and cash equivalents	$	8,442	$	26,330
Restricted cash		250		250
Total cash, cash equivalents and restricted cash	$	8,692	$	26,580

Inventories

6 Months Ended

Jun. 30, 2023

Inventories

Inventories

Note 5. Inventories

As of June 30, 2023 and December 31, 2022, inventories consisted of the following:

(in thousands)	June 30, 2023		December 31, 2022
Raw materials	$	1,334	$	944
Work in process		2,194		2,879
Finished goods		191		353
Total inventories, net		3,719		4,176
Less: noncurrent inventories		1,351		2,194
Current inventories	$	2,368	$	1,982

The reserve for obsolete inventory was $0.3 million and $0.7 million as of June 30, 2023 and December 31, 2022, respectively. The Company records charges for obsolete inventory in cost of goods sold. As of June 30, 2023 and December 31, 2022, noncurrent inventory was comprised of approximately $0.6 million and $0.1 million in raw materials and $0.8 million and $2.1 million of work in process, respectively. Inventory classified under the category “Work in process” consists of prefabricated assembled product.

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Income Statement [Abstract]
Net sales	$ 3,551	$ 2,157	$ 6,331	$ 4,056
Cost of goods sold	585	358	1,043	718
Gross profit	2,966	1,799	5,288	3,338
Operating expenses
Research and development	1,155	1,341	2,964	2,275
Selling, general and administrative	6,799	6,278	13,509	12,464
Total operating expenses	7,954	7,619	16,473	14,739
Loss from operations	(4,988)	(5,820)	(11,185)	(11,401)
Other (income) expense
Interest and other income	(85)	(38)	(204)	(42)
Other expense				5
Total other (income) expense	(85)	(38)	(204)	(37)
Loss before income taxes	(4,903)	(5,782)	(10,981)	(11,364)
Benefit from income taxes		445	211	445
Net loss	$ (4,903)	$ (5,337)	$ (10,770)	$ (10,919)
Net loss per share of common stock - Basic (in dollars per share)	$ (1.03)	$ (1.2)	$ (2.27)	$ (2.25)
Net loss per share of common stock - Diluted (in dollars per share)	$ (1.03)	$ (1.2)	$ (2.27)	$ (2.25)
Weighted average common shares outstanding - Basic (in shares)	4,751	4,448	4,747	4,853
Weighted average common shares outstanding - Diluted (in shares)	4,751	4,448	4,747	4,853

Leases - Supplemental Balance Sheet Information for Operating Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Operating leases:
Operating lease right of use assets	$ 534	$ 565
Operating lease liabilities:
Current portion of operating lease liabilities	81	74
Noncurrent operating lease liabilities	583	625
Total operating lease liabilities	$ 664	$ 699
Weighted average remaining lease term (in years)	5 years 7 months 6 days	6 years 1 month 6 days
Weighted average discount rate	13.80%	13.80%

Going Concern, Significant Risks and Uncertainties (Tables)

6 Months Ended

Jun. 30, 2023

Going Concern, Significant Risks and Uncertainties

Schedule of revenue channels accounted for 10% or more of the Company's net sales

	Three months ended June 30,				Six months ended June 30,
	2023		2022		2023		2022
Revenue channel:
Rx gammaCore - VA/DoD	58.6	%	55.1	%	59.8	%	60.4	%
National Health Service	9.8	%	16.4	%	9.9	%	15.3	%

Net Loss Per Share - Schedule of Common Stock Equivalents Excluded from Computation of Diluted Loss per Share (Details) - shares shares in Thousands	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	479	492
Outstanding stock options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	335	418
Restricted stock and unit awards
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	143	63
Stock purchase warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1	11

Revenue - Additional Information (Details)	6 Months Ended
Revenue - Additional Information (Details)	Jun. 30, 2023
Revenue
Payment term for customers	30 days

Inventories - Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Inventories
Raw materials	$ 1,334	$ 944
Work in process	2,194	2,879
Finished goods	191	353
Total inventories, net	3,719	4,176
Less: noncurrent inventories	1,351	2,194
Current inventories	$ 2,368	$ 1,982

Stock Based Compensation (Tables)

6 Months Ended

Jun. 30, 2023

Stock Based Compensation

Summary of Activity Related to Stock Options

	Number of Options (in thousands)			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (Years)
Outstanding, January 1, 2023	$	440		$	55.65		7.5
Granted		3
Exercised		—
Cancelled		(108	)
Outstanding, June 30, 2023	$	335		$	58.79		7.0
Exercisable, June 30, 2023	$	236		$	76.92		6.6

Summary of Activity Related to Restricted Stock and Deferred Stock Units Granted

	Number of Shares (in thousands)			Weighted Average Grant Date Fair Value
Nonvested, January 1, 2023		127		$	11.85
Granted		—
Vested		(11	)
Cancelled		—
Nonvested, June 30, 2023		116		$	11.06

Schedule of Recognized Stock Compensation for Equity Awards

	Three months ended June 30,					Six months ended June 30,
(in thousands)	2023		2022		2023		2022
Selling, general and administrative	$	115	$	676	$	625	$	1,381
Research and development		61		68		118		134
Cost of goods sold		7		8		12		14
Total expense	$	183	$	752	$	755	$	1,529

Summary of Weighted Average Assumptions Used in Valuing Plans

	Six months ended June 30,
	2023				2022
Fair value at grant date	$	3.46		$	7.95
Expected volatility	114.0		%		84.0	%
Risk-free interest rate	3.9		%		1.7	%
Expected holding period, in years	6.0				6.0
Dividend yield		—	%		—	%

Leases (Tables)

6 Months Ended

Jun. 30, 2023

Leases

Schedule of supplemental balance sheet information for operating leases

(in thousands)	June 30, 2023			December 31, 2022
Operating leases:
Operating lease right of use assets	$	534		$	565
Operating lease liabilities:
Current portion of operating lease liabilities		81			74
Noncurrent operating lease liabilities		583			625
Total operating lease liabilities	$	664		$	699
Weighted average remaining lease term (in years)		5.6			6.1
Weighted average discount rate		13.8	%		13.8	%

Schedule of future minimum lease payments under non-cancellable operating leases

(in thousands)
Remainder of 2023	$	82
2024		168
2025		171
2026		161
2027		157
2028 and thereafter		216
Total future minimum lease payments		955
Less: Amounts representing interest		(291	)
Total	$	664

Going Concern, Significant Risks and Uncertainties - Additional Information (Details) $ in Millions		3 Months Ended		6 Months Ended
	Jul. 31, 2023 USD ($)	Jun. 30, 2023 facility	Jun. 30, 2022 facility	Jun. 30, 2023 facility	Jun. 30, 2022 facility
Risks And Uncertainties [Line Items]
Revenue percentage		59.80%		59.80%
Federal supply schedule expire date				Jan. 15, 2024
Net Sales \| Revenue from Rights Concentration Risk \| VA/DoD [Member]
Risks And Uncertainties [Line Items]
Percentage of net sales		58.60%	55.10%	59.80%	60.40%
Net Sales \| Revenue from Rights Concentration Risk \| National Health Service [Member]
Risks And Uncertainties [Line Items]
Percentage of net sales		9.80%	16.40%	9.90%	15.30%
Net Sales \| Revenue from Rights Concentration Risk \| VA/DoD and National Health Service
Risks And Uncertainties [Line Items]
Percentage of net sales				10.00%	10.00%
Securities Purchase Agreement \| Subsequent Event
Risks And Uncertainties [Line Items]
Sale of Stock, Consideration Received on Transaction \| $	$ 7.5
Zero facilities [Member] \| VA/DoD [Member]
Risks And Uncertainties [Line Items]
Number of facilities				0
Zero facilities [Member] \| Minimum \| Net Sales \| Revenue from Rights Concentration Risk \| VA/DoD [Member]
Risks And Uncertainties [Line Items]
Percentage of net sales				10.00%
Facility one [Member]
Risks And Uncertainties [Line Items]
Number of facilities		1
Facility one [Member] \| National Health Service [Member]
Risks And Uncertainties [Line Items]
Number of channels			1		1
Number of facilities				1
Facility one [Member] \| Minimum \| Net Sales \| Revenue from Rights Concentration Risk \| National Health Service [Member]
Risks And Uncertainties [Line Items]
Percentage of net sales		10.00%	10.00%	10.00%	10.00%

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 8,442	$ 17,712
Restricted cash	250	250
Accounts receivable, net	238	401
Inventories, net	2,368	1,982
Prepaid expenses and other current assets	106	828
Total current assets	11,404	21,173
Inventories, noncurrent	1,351	2,194
Property and equipment, net	114	50
Operating lease right of use assets, net	534	565
Other assets, net	819	774
Total assets	14,222	24,756
Current liabilities:
Accounts payable	2,284	2,129
Accrued expenses and other current liabilities	4,210	4,842
Current portion of operating lease liabilities	81	74
Total current liabilities	6,575	7,045
Noncurrent liabilities:
Operating lease liabilities, noncurrent	583	625
Total liabilities	7,158	7,670
Commitments and contingencies
Mezzanine Equity:
Preferred Stock, par value $0.001 per share; 10,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 0 shares issued and outstanding at June 30, 2023 and 71,173 issued and outstanding at December 31, 2022 ($0.001 per share liquidation value)
Stockholders' equity:
Common Stock, par value $0.001 per share; 500,000,000 shares authorized at June 30, 2023 and December 31, 2022; 4,752,475 shares issued and outstanding at June 30, 2023 and 4,744,886 shares issued and outstanding at December 31, 2022	5	5
Additional paid-in capital	164,275	163,520
Accumulated deficit	(157,140)	(146,370)
Accumulated other comprehensive loss	(76)	(69)
Total equity	7,064	17,086
Total liabilities and equity	$ 14,222	$ 24,756

Leases

6 Months Ended

Jun. 30, 2023

Leases

Leases

Note 6. Leases

For each of the three and six months ended June 30, 2023 and 2022 the Company recognized lease expense of $38,000 and $76,000. This expense does not include non-lease components associated with the lease agreements as the Company elected not to include such charges as part of the lease expense.

Supplemental Balance Sheet Information for Operating Leases:

(in thousands)	June 30, 2023			December 31, 2022
Operating leases:
Operating lease right of use assets	$	534		$	565
Operating lease liabilities:
Current portion of operating lease liabilities		81			74
Noncurrent operating lease liabilities		583			625
Total operating lease liabilities	$	664		$	699
Weighted average remaining lease term (in years)		5.6			6.1
Weighted average discount rate		13.8	%		13.8	%

Future minimum lease payments under non-cancellable operating leases as of June 30, 2023:

(in thousands)
Remainder of 2023	$	82
2024		168
2025		171
2026		161
2027		157
2028 and thereafter		216
Total future minimum lease payments		955
Less: Amounts representing interest		(291	)
Total	$	664

Stock Based Compensation - Summary of Activity Related to Stock Options (Details) - $ / shares shares in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2022
Number of Options
Number of Options, Outstanding, Begining	440
Number of Options, Granted	3
Number of Options, Exercised
Number of Options, Cancelled	(108)
Number of Options, Outstanding, Ending	335	440
Number of Options, Exercisable	236
Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding, Begining	$ 55.65
Weighted Average Exercise Price, Outstanding, Ending	58.79	$ 55.65
Weighted Average Exercise Price, Exercisable	$ 76.92
Weighted Average Remaining Contractual Term (Years), Outstanding	7 years	7 years 6 months
Weighted Average Remaining Contractual Term (Years), Exercisable	6 years 7 months 6 days

Subsequent Events - Additional Information (Details) - Subsequent Event - USD ($)	Jul. 31, 2023	Jul. 05, 2023
Securities Purchase Agreement
Subsequent Event [Line Items]
Sale of stock, price per share	$ 4.4125
Sale of Stock, Consideration Received on Transaction	$ 7,500,000
Securities Purchase Agreement \| Common Stock \| Warrant
Subsequent Event [Line Items]
Class of Warrant or Right, Period from which Warrants or Rights Exercisable	6 months
Class of warrant or right, exercise price of warrants or rights	$ 4.35
Class of Warrant or Right, Expiration Period	5 years
First SPA \| Common Stock
Subsequent Event [Line Items]
Aggregate number of shares issued	1,675,914
First SPA \| Common Stock \| Warrant \| Maximum
Subsequent Event [Line Items]
Aggregate number of shares to be issued for common stock purchase warrants	837,955
Second SPA \| Common Stock \| Private Placement Transaction
Subsequent Event [Line Items]
Aggregate number of shares issued	169,968
Second SPA \| Common Stock \| Private Placement Transaction \| Warrant \| Maximum
Subsequent Event [Line Items]
Aggregate number of shares issued	84,982
Commercial Insurance Premium Finance and Security Agreement
Subsequent Event [Line Items]
Debt instrument, face amount		$ 618,000
Debt instrument, term		10 months
Annual interest rate of borrowing		6.03%
Debt instrument, frequency of periodic payment		monthly
Debt instrument, installment payment		$ 62,000

Severance and other related charges

6 Months Ended

Jun. 30, 2023

Severance and other related charges

Severance and other related charges

Note 13. Severance and other related charges

In the first quarter of 2023, the Company entered into separation agreements with two former employees which agreements required an aggregate of payments of $332,000. The charge for these payments is included in Selling, general and administrative expense in the accompanying Condensed Statement of Operations for the six months ended June 30, 2023. As of June 30, 2023, the Company has an outstanding payable of $207,000 in connection with these charges. This outstanding payable is included in Accrued expenses and other current liabilities in the accompanying Condensed Consolidated Balance Sheet as of June 30, 2023 (see Note 7).

Accrued Expenses and Other Current Liabilities (Details) - USD ($)		3 Months Ended	6 Months Ended
	Jul. 05, 2022	Jun. 30, 2023	Jun. 30, 2023
Accrued Expenses and Other Current Liabilities [Line Item]
Interest expense		$ 2,250	$ 3,867
Finance and Security Agreement
Accrued Expenses and Other Current Liabilities [Line Item]
Monthly installments payable	$ 783,000
Debt instrument, term	9 months
Interest rate on the loan	2.49%

Accrued Expenses and Other Current Liabilities (Tables)

6 Months Ended

Jun. 30, 2023

Accrued Expenses and Other Current Liabilities

Schedule of accrued expenses and other current liabilities

(in thousands)	June 30, 2023		December 31, 2022
Accrued professional fees	$	483	$	524
Accrued bonuses and incentive compensation		1,436		2,042
Accrued litigation legal fees expense		1,035		1,001
Accrued insurance expense		24		264
Accrued vacation and other employee related expenses		739		534
Accrued severance and other related charges		207		—
Accrued valued-added tax		180		133
Deferred revenue		36		152
Other		70		192
	$	4,210	$	4,842

Leases - Additional Information (Details) - USD ($)	3 Months Ended	6 Months Ended
Leases - Additional Information (Details) - USD ($)	Jun. 30, 2023	Jun. 30, 2023
Lessor, Lease, Description [Line Items]
Recognized lease expenses	$ 38,000	$ 76,000

Shareholders' Equity	6 Months Ended
Shareholders' Equity	Jun. 30, 2023
Shareholders' Equity
Shareholders' Equity	Note 8. Shareholders' Equity Reverse Stock Split On February 13, 2023, the Company held a special meeting (the “Special Meeting”) of stockholders of the Company. At the Special Meeting, the Company’s shareholders voted to approve an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio between 1-for-5 and 1-for-50. Following the Special Meeting, the board of directors of the Company approved a 1-for-15 Reverse Stock Split. The Reverse Stock Split became effective on February 15, 2023. Upon the effectiveness of the Reverse Stock Split, every 15 shares of common stock were automatically combined and converted into one share of common stock. Appropriate adjustments were also made to all outstanding derivative securities of the Company, including all outstanding equity awards and warrants. No fractional shares were issued in connection with the Reverse Stock Split. Instead, all fractional shares received a cash payment based on the closing sales price on the Nasdaq Capital Market of the Company’s common stock on February 14, 2023. Redemption and Elimination of Series A Preferred Stock All shares of Series A Preferred Stock that were not present in person or by proxy as of immediately prior to the opening of the polls at the Special Meeting were automatically redeemed by the Company (the “Initial Redemption”). Any outstanding shares of Series A Preferred Stock that had not been so redeemed were redeemed automatically upon the approval at the Special Meeting of the Reverse Stock Split (the “Subsequent Redemption”). Each share of Series A Preferred Stock redeemed was entitled to receive an amount equal to $0.01 in cash for each 10 whole shares of Series A Preferred Stock owned immediately prior to the Redemption. On March 6, 2023, the Company filed a certificate of elimination (the “Certificate of Elimination”), with the Secretary of State of the State of Delaware with respect to the Series A Preferred Stock. The Certificate of Elimination (i) eliminated the previous designation of 80,000 shares of Series A Preferred Stock from the Company’s Certificate of Incorporation, none of which were outstanding at the time of the filing of the Certificate of Elimination, and (ii) caused such shares of Series A Preferred Stock to resume their status as authorized but unissued and non-designated shares of preferred stock.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022
Accrued Liabilities Current [Abstract]
Accrued professional fees	$ 483	$ 524
Accrued bonuses and incentive compensation	1,436	2,042
Accrued litigation legal fees expense	1,035	1,001
Accrued insurance expense	24	264
Accrued vacation and other employee related expenses	739	534
Accrued severance and other related charges	207
Accrued valued-added tax	180	133
Deferred revenue	36	152
Other	70	192
Accrued expenses and other current liabilities	$ 4,210	$ 4,842

Revenue - Summary of Net Sales Disaggregated by Channel (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Disaggregation Of Revenue [Line Items]
Total Net Sales	$ 3,551	$ 2,157	$ 6,331	$ 4,056
Rx gammaCore - Department of Veteran Affairs and Department of Defense [Member]
Disaggregation Of Revenue [Line Items]
Total Net Sales	2,081	1,190	3,786	2,430
Rx gammaCore - U.S. Commercial [Member]
Disaggregation Of Revenue [Line Items]
Total Net Sales	441	465	871	741
Outside the United States [Member]
Disaggregation Of Revenue [Line Items]
Total Net Sales	424	467	834	772
Truvaga [Member]
Disaggregation Of Revenue [Line Items]
Total Net Sales	290		437
TAC-STIM [Member]
Disaggregation Of Revenue [Line Items]
Total Net Sales	311		399
Other [Member]
Disaggregation Of Revenue [Line Items]
Total Net Sales	$ 4	$ 35	$ 4	$ 113

- Definition

+ References

+ Details

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

(a)	Basis of Presentation

(b)	Principles of Consolidation

(c)	Use of Estimates

(d)	Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash to the balance reflected on the Condensed Consolidated Statement of Cash Flows for June 30, 2023 and 2022:

(in thousands)	June 30, 2023		June 30, 2022
Cash and cash equivalents	$	8,442	$	26,330
Restricted cash		250		250
Total cash, cash equivalents and restricted cash	$	8,692	$	26,580

As of June 30, 2023 and December 31, 2022, cash equivalents represented funds held in a money market account.

(e)	Restricted Cash

(f)	Licensed Products

(g)	Prior Year Presentation

Prior year presentation has been conformed to current year presentation.

Subsequent Events

6 Months Ended

Jun. 30, 2023

Subsequent Events

Subsequent Events

Note 14. Subsequent Events

Securities Purchase Agreements

On July 31, 2023, the Company entered into a Securities Purchase Agreement (“First SPA”) in connection with a registered direct offering and concurrent private placement with certain institutional and accredited investors pursuant to which the Company issued and sold an aggregate of 1,675,914 shares of common stock (or pre-funded common stock purchase warrants) and warrants to purchase up to an aggregate of 837,955 shares of common stock. On July 31, 2023, the Company also entered into a Securities Purchase Agreement (“Second SPA”) in connection with a concurrent private placement with certain of the Company’s officers and directors pursuant to which the Company issued and sold 169,968 shares of common stock and warrants to purchase up to an aggregate of 84,982 shares of common stock. The combined effective offering price of the securities sold pursuant to the First SPA and the Second SPA was $4.4125 per share of common stock and related common stock purchase warrant. The common stock purchase warrants will be exercisable commencing six months after the date of issuance at a price of $4.35 per share and will expire five years after they first become exercisable. The net proceeds to the Company resulting from the First SPA and Second SPA was approximately $7.5 million, after deducting the placement agent fees and expenses, and other offering expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the common stock purchase warrants sold in the concurrent private placements. The Company currently intends to use the net proceeds from these sales for sales and marketing, working capital, and general corporate purposes.

Finance and Security Agreement

On July 5, 2023, the Company entered into a Commercial Insurance Premium Finance and Security Agreement (the "2023 Agreement"). The 2023 Agreement provides for a single borrowing by the Company of approximately $618,000 with a ten-month term and an annual interest rate of 6.03%. The proceeds from this transaction were used to partially fund the premiums due under certain of the Company's insurance policies. The amounts payable are secured by the Company's rights under such policies. The Company began paying monthly installments of approximately $62,000 in July 2023.

Going Concern, Significant Risks and Uncertainties - Schedule of company's net sales (Details) - Net Sales - Revenue from Rights Concentration Risk	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
VA/DoD [Member]
Concentration Risk [Line Items]
Revenue, percentage	58.60%	55.10%	59.80%	60.40%
National Health Service [Member]
Concentration Risk [Line Items]
Revenue, percentage	9.80%	16.40%	9.90%	15.30%

Contingencies

6 Months Ended

Jun. 30, 2023

Contingencies

Contingencies

Note 12. Contingencies

Stockholders Litigation

On July 8, 2019, and August 1, 2019, purported stockholders of the Company served putative class action lawsuits in the Superior Court of New Jersey for Somerset County, captioned Paul Kuehl vs. electroCore, Inc., et al., Docket No. SOM-L 000876-19 and Shirley Stone vs. electroCore, Inc., et al., Docket No. SOM-L 001007-19, respectively. In addition to the Company, the defendants include present and past directors and officers, Evercore Group L.L.C., Cantor Fitzgerald & Co., JMP Securities LLC and BTIG, LLC, the underwriters for its IPO; and two of the Company’s stockholders. On August 15, 2019, the Superior Court entered an order consolidating the Kuehl and Stone actions, which proceeded under Docket No. SOM-L 000876-19.

Each plaintiff was appointed a co-lead plaintiff. The plaintiffs filed a consolidated amended complaint, which sought certification of a class of stockholders who purchased common stock in the IPO or whose purchases are traceable to that offering. The consolidated amended complaint alleged that the defendants violated Sections 11, 12(a)(2) and 15 of the Securities Act with respect to the registration statement and related prospectus for the IPO. The complaint sought unspecified compensatory damages, interest, costs and attorneys’ fees.

On December 14, 2021, the Superior Court granted the defendants’ motion to dismiss based on the federal forum selection clause in our certificate of incorporation with prejudice and granted the defendants’ motion to dismiss without prejudice. On January 27, 2022, the plaintiffs filed a notice of appeal to the Appellate Division. The appeal was fully briefed and oral argument was heard on April 19, 2023. On May 15, 2023, the Appellate Division unanimously affirmed the dismissal. The time for further appeals has expired.

On September 26, 2019, and October 31, 2019, purported stockholders of the Company served putative class action lawsuits in the United States District Court for the District of New Jersey captioned Allyn Turnofsky vs. electroCore, Inc., et al., Case 3:19-cv-18400, and Priewe vs. electroCore, Inc., et al., Case 1:19-cv-19653, respectively. In addition to the Company, the defendants include present and past directors and officers, and Evercore Group L.L.C., Cantor Fitzgerald & Co., JMP Securities LLC and BTIG, LLC, the underwriters for the IPO. The plaintiffs each seek to represent a class of stockholders who (i) purchased the Company’s common stock in the IPO or whose purchases are traceable to the IPO, or (ii) who purchased common stock between the IPO and September 25, 2019. The complaints each alleged that the defendants violated Sections 11 and 15 of the Securities Act and Sections 10(b) and 20(a) of the Exchange Act, with respect to (i) the registration statement and related prospectus for the IPO, and (ii) certain post-IPO disclosures filed with the SEC. The complaints sought unspecified compensatory damages, interest, costs and attorneys’ fees. The Priewe case was voluntarily dismissed on February 19, 2020.

In the Turnofsky case, on November 25, 2019, several plaintiffs and their counsel moved to be selected as lead plaintiff and lead plaintiff’s counsel. On April 24, 2020, the Court granted the motion of Carole Tibbs and the firm Bragar, Eagel & Squire, P.C. On July 17, 2020, the plaintiffs filed an amended complaint in Turnofsky. In addition to the prior claims, the amended complaint added an additional director defendant and two investors as defendants and adds a claim against the Company and the underwriters for violating Section 12(a)(2) of the Securities Act.

On September 15, 2020, the Company and the other defendants filed a motion to dismiss the amended complaint for failure to state a claim. On November 6, 2020, the plaintiffs filed their opposition to the motion to dismiss. The Company and the other defendants filed reply papers in support of the motion on December 7, 2020. Argument of the motion to dismiss occurred on June 18, 2021. On August 13, 2021, the Court dismissed the amended complaint with leave to re-plead. On October 4, 2021, the plaintiffs filed a second amended complaint in the Turnofsky case. The defendants moved to dismiss, and briefing on the motion was complete on January 7, 2022. On July 13, 2023, the court dismissed the second amended complaint with leave to re-plead. The plaintiffs have until August 14, 2023, to file a third amended complaint if they so desire.

On March 4, 2021, purported stockholder Richard Maltz brought a purported stockholder derivative action in the United States District Court for the District of New Jersey. The action is captioned Richard Maltz, derivatively on behalf of electroCore, Inc., vs. Francis R. Amato, et al., Case 3:21-cv-04135. The defendants include present and past directors and officers of the Company. The plaintiff purports to pursue derivative claims on behalf of the Company in connection with the IPO and actions occurring between the IPO and September 25, 2019. The complaint alleges that demand on the board of directors is excused. The complaint purports to allege claims against the defendants for violating Section 14(a) of the Exchange Act, breaching fiduciary duties, unjust enrichment and waste of corporate assets. The complaint also purports to allege claims for contribution in connection with the Turnofsky case described above, pursuant to Section 11(f) of the Securities Act and Sections 10(b) and 21D of the Exchange Act. The complaint seeks unspecified compensatory damages, interest, costs and attorneys’ fees; declaratory relief; and an order requiring changes to corporate governance and internal procedures and a vote on proposed amendments to the Bylaws and Certificate of Incorporation.

On March 8, 2021, purported stockholder Erin Yuson brought a purported stockholder derivative action in the United States District Court for the District of New Jersey. The action is captioned Erin Yuson, derivatively on behalf of electroCore, Inc., vs. Francis R. Amato, et al., Case 3:21-cv-04481. The defendants include present and past directors and officers of the Company. The plaintiff purports to pursue derivative claims on behalf of the Company in connection with a 2019 proxy statement and actions occurring from the IPO through September 25, 2019. The complaint alleges that demand on the board of directors is excused. The complaint purports to allege claims against the defendants for violating Section 14(a) of the Exchange Act and breaching fiduciary duties. The complaint seeks unspecified compensatory damages, interest, costs and attorneys’ fees; declaratory relief; and an order requiring changes to corporate governance and internal procedures and a vote on proposed amendments to the Bylaws and Certificate of Incorporation.

The plaintiffs in the Maltz and Yuson derivative actions agreed to consolidate and stay those actions. The actions are stayed until and through the resolution of any motion for summary judgment in the Turnofsky federal securities class action. A stipulation to that effect was filed by the plaintiffs on April 14, 2021, and ordered by the court on April 30, 2021. On June 9, 2023, the cases were administratively dismissed without prejudice.

The Company intends to continue to vigorously defend itself in these matters. However, in light of, among other things, the preliminary stage of these litigation matters, the Company is unable to determine the reasonable probability of loss or a range of potential loss. Accordingly, the Company has not established an accrual for potential losses, if any, that could result from any unfavorable outcome, and there can be no assurance that these litigation matters will not result in substantial defense costs and/or judgments or settlements that could adversely affect the Company’s financial condition.

The Company is subject to various claims, complaints and legal actions in the normal course of business from time to time. The Company is not aware of any further currently pending litigation for which it believes the outcome could have a material adverse effect on its operations or financial position. The Company expenses associated legal fees including those relating to the stockholder litigation described in this Note 12 in the period they are incurred.

Inventories (Tables)

6 Months Ended

Jun. 30, 2023

Inventories

Schedule of inventories stated at lower of cost or market

(in thousands)	June 30, 2023		December 31, 2022
Raw materials	$	1,334	$	944
Work in process		2,194		2,879
Finished goods		191		353
Total inventories, net		3,719		4,176
Less: noncurrent inventories		1,351		2,194
Current inventories	$	2,368	$	1,982

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Statement Of Income And Comprehensive Loss [Abstract]
Net loss	$ (4,903)	$ (5,337)	$ (10,770)	$ (10,919)
Other comprehensive loss:
Foreign currency translation adjustment	(63)	(58)	(7)	(85)
Other comprehensive income	(63)	(58)	(7)	(85)
Comprehensive loss	$ (4,966)	$ (5,395)	$ (10,777)	$ (11,004)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

Revenue (Tables)

6 Months Ended

Jun. 30, 2023

Revenue

Schedule of net sales disaggregated by channel

(in thousands)	Three months ended June 30,				Six months ended June 30,
Channel		2023		2022		2023		2022
Rx gammaCore - Department of Veteran Affairs and Department of Defense	$	2,081	$	1,190	$	3,786	$	2,430
Rx gammaCore - U.S. Commercial		441		465		871		741
Outside the United States		424		467		834		772
Truvaga		290		—		437		—
TAC-STIM		311		—		399		—
Other		4		35		4		113
	$	3,551	$	2,157	$	6,331	$	4,056

Schedule of net sales disaggregated by geographic market

	Three months ended June 30,				Six months ended June 30,
(in thousands)		2023		2022		2023		2022
Product revenue
United States	$	3,127	$	1,690	$	5,497	$	3,284
United Kingdom		384		355		705		621
Other		22		64		65		103
License revenue
Japan		18		48		64		48
Total Net Sales	$	3,551	$	2,157	$	6,331	$	4,056

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2023	Aug. 03, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Trading Symbol	ECOR
Entity Registrant Name	electroCore, Inc.
Entity Central Index Key	0001560258
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,985,043
Entity File Number	001-38538
Entity Tax Identification Number	20-3454976
Entity Address, Address Line One	200 Forge Way
Entity Address, Address Line Two	Suite 205
Entity Address, City or Town	Rockaway
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07866
City Area Code	(973)
Local Phone Number	290-0097
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	71,173
Preferred stock, shares outstanding	0	71,173
Preferred stock, liquidation value per share		$ 0.001
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	4,752,475	4,744,886
Common stock, shares outstanding	4,752,475	4,744,886

Summary of Significant Accounting Policies - Schedule of cash equivalents and restricted cash (Details) - USD ($) $ in Thousands	Jun. 30, 2023	Dec. 31, 2022	Jun. 30, 2022
Accounting Policies [Abstract]
Cash and cash equivalents	$ 8,442	$ 17,712	$ 26,330
Restricted cash	250		250
Total cash, cash equivalents and restricted cash	$ 8,692		$ 26,580

Income Taxes - Additional Information (Details)	Jan. 10, 2023 USD ($)
Operating Loss Carryforwards [Line Items]
Proceeds from operating activity	$ 211,000

Stock Based Compensation - Summary of Weighted Average Assumptions Used in Valuing Plans (Details) - $ / shares	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Stock Based Compensation
Fair value at grant date	$ 3.46	$ 7.95
Expected volatility	114.00%	84.00%
Risk-free interest rate	3.90%	1.70%
Expected holding period, in years	6 years	6 years
Dividend yield

Income taxes

6 Months Ended

Jun. 30, 2023

Income Taxes

Income Taxes

Note 10. Income Taxes

The Company may be eligible, from time to time, to receive cash from the sale of its net operating losses under New Jersey's Department of the Treasury - Division of Taxation NOL Transfer Program. On January 10, 2023, the Company received a net cash payment of $211,000 from the sale of its New Jersey state net operating losses.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details